NCT01859533

Brief Summary

Evaluating the effect of early application of Continuous positive airway pressure (CPAP) via Neopuff in cases of transient tachypnea of the newborn(TTN) and its role in decreasing the duration and complication of TTN.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Nov 2011

Shorter than P25 for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2011

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2013

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2013

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

May 16, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 22, 2013

Completed
Last Updated

May 22, 2013

Status Verified

May 1, 2013

Enrollment Period

1.2 years

First QC Date

May 16, 2013

Last Update Submit

May 20, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Need for admissions to NICU secondary to TTN

    24 hours

Secondary Outcomes (7)

  • Levels of plasma brain natriuretic peptide and clinical outcome [Time Frame: 24 hours].

    24 hours

  • Duration of tachypnea.

    until discharge

  • Duration and type of oxygen therapy.

    ntil discharge

  • Antibiotic treatment.

    until discharge

  • Incidence of pulmonary air leaks

    ntil discharge

  • +2 more secondary outcomes

Study Arms (2)

Neopuff group

EXPERIMENTAL

includes 34 newborns showing signs of TTN who received CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).

Device: Neopuff

Control group

NO INTERVENTION

includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010).

Interventions

NeopuffDEVICE

* Group I neonates (Experimental group) includes 30 newborns showing signs of TTN who will receive administration of CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand). * Group II neonates (Control group) includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010).

Also known as: Early CPAP
Neopuff group

Eligibility Criteria

AgeUp to 2 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Near term infants (36-37 weeks gestational age) and Full term infants (38-41 weeks gestational age).
  • Presence of signs of respiratory distress (Tachypnea, intercostal and subcostal retractions, nasal flaring and grunting) evident shortly after birth.
  • Cesarean section (CS) was defined as elective when surgery was performed before the onset of labor, with all other cases defined as secondary CS.

You may not qualify if:

  • Presence of any of the risk factors for neonatal sepsis such as Prolonged Rupture of Membranes for ≥48 hours (PROM), maternal fever, maternal chorioamnionitis or positive maternal GBS colonization.
  • Presence of any other cause of respiratory distress, eg.
  • congenital malformations affecting the cardiorespiratory system ,
  • chromosomal aberrations,
  • depression at birth (Apgar score at 5 minutes of \< 7 or umbilical artery pH of \< 7.10),
  • fetal hydrops,
  • persistent pulmonary hypertension,
  • and meconium aspiration syndrome.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Transient Tachypnea of the Newborn

Condition Hierarchy (Ancestors)

Respiratory Distress Syndrome, NewbornRespiratory Distress SyndromeLung DiseasesRespiratory Tract DiseasesRespiration DisordersTachypneaInfant, Premature, DiseasesInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Rania A. El-Farrash, MD, PhD

    Associate Professor of Pediatrics, Department of Pediatrics, Ain Shams University, Cairo, Egypt

    PRINCIPAL INVESTIGATOR
  • Amani O. Mahmoud, MD

    Professor of Pediatrics, Department of Pediatrics, Ain Shams University, Cairo, Egypt

    STUDY CHAIR
  • Enas H. Abdul-Hady, M.B.B.Ch

    Ministry of Health

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Pediatrics

Study Record Dates

First Submitted

May 16, 2013

First Posted

May 22, 2013

Study Start

November 1, 2011

Primary Completion

January 1, 2013

Study Completion

May 1, 2013

Last Updated

May 22, 2013

Record last verified: 2013-05